The combination of nab-paclitaxel (Abraxane) and bevacizumab (Avastin) eradicates highly aggressive metastatic breast cancer in a preclinical model, Sophia Ran, PhD, reported at the SABCS (abstract 74).
When used as adjuvant therapy for node-positive breast cancer, the combination of high-dose chemotherapy (HDC) and stem cell transplantation modestly improves relapse-free survival relative to standard-dose chemotherapy (SDC). But it offers at best minimal benefit in terms of overall survival, according to a meta-analysis presented at SABCS.
Middle-aged women today are about half as likely as their counterparts 25 years ago to die from breast cancer, thanks in large part to the collective effects of modern therapies, according to new data reported at SABCS. Results of the 2005-2006 update of the worldwide overview presented by Richard Peto, PhD, on behalf of the Early Breast Cancer Trialists’ Collaborative Group were based on data from roughly 350,000 women and 400 randomized trials.
Investigational agent denosumab is safe and efficacious for attenuating bone loss among women taking adjuvant aromatase inhibitors for breast cancer, according to a phase III randomized double-blind placebo-controlled trial reported at SABCS (abstract 47).
Anthracyclines are widely used in the adjuvant treatment of breast cancer, but this practice is being questioned as emerging data show benefits to be restricted to certain subsets of patients.
More data have emerged to suggest that MRI is more sensitive than mammography, though less specific, in screening women at high risk for breast cancer occurrence. Moreover, annual screening picks up a high number of ductal carcinomas in situ (DCIS), but also identifies tumors that are already large at diagnosis among BRCA1 mutation carriers.
Two new genomic assays may provide prognostic and predictive information for individual patients with breast cancer, thereby helping to guide treatment decisions, according to data from a pair of studies presented at SABCS.
Some breast cancer patients with positive sentinel lymph nodes have factors associated with a low probability of having any other positive nodes and may therefore be able to safely skip completion axillary dissection, new data show.
Preliminary findings from the I-SPY trial of neoadjuvant chemotherapy are a testament to the complexity and heterogeneity of locally advanced tumors and validate the concept that “biology should dictate the ‘what’ and the ‘how’ of treatment,” according to Laura Esserman, MD, Director of the Breast Cancer Center and Professor of Surgery and Radiation at the University of California, San Francisco School of Medicine.
Breast cancer patients with isolated tumor cells or micrometastases in sentinel nodes do not have poorer disease-free or overall survival than their counterparts with negative sentinel nodes, researchers reported at the SABCS (abstract 52).